Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: Analysis of 533 adult patients who underwent transplantation at king's college hospital

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 1, 2015, Pages 60-66

  Wang, Meng ^a   Wang, Wenjia ^b   Abeywardane, Ayesha ^a   Adikarama, Malinthi ^a   McLornan, Donal ^a   Raj, Kavita ^a   de Lavallade, Hugues ^a   Devereux, Stephen ^a   Mufti, Ghulam J ^a   Pagliuca, Antonio ^a   Potter, Victoria T ^a   Mijovic, Aleksandar ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Autoimmune hemolytic anemia; Mortality

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; COMPLEMENT COMPONENT C3D; CYCLOSPORIN; DANAZOL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MYCOPHENOLIC ACID; PREDNISOLONE; RAPAMYCIN; RHESUS ANTIBODY; RHESUS E ANTIBODY; RITUXIMAB;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PLASMAPHERESIS; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; SPLENECTOMY; UNRELATED DONORS; YOUNG ADULT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANEMIA, HEMOLYTIC, AUTOIMMUNE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PATHOLOGY; SIBLING; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM; UNIVERSITY HOSPITAL;

ADULT; ANEMIA, HEMOLYTIC, AUTOIMMUNE; FEMALE; GREAT BRITAIN; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SIBLINGS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84927175393     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.09.009     Document Type: Article

References (31)

1. Holbro A., Abinun M., Daikeler T. Management of autoimmune diseases after haematopoietic stem cell transplantation. Br J Haematol 2012, 157:281-290.
2. Daikeler T., Labopin M., Ruggeri A., et al. New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. Blood 2013, 121:1059-1064.
3. Faraci M., Zecca M., Pillon M., et al. Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience. Biol Blood Marrow Transplant 2014, 20:272-278.
4. Drobyski W.R., Potluri J., Sauer D., Gottschall J.L. Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1996, 17:1093-1099.
5. Chen F.E., Owen I., Savage D., et al. Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. Bone Marrow Transplant 1997, 19:491-495.
6. Sanz J., Arriaga F., Montesinos P., et al. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. Bone Marrow Transplant 2007, 39:555-561.
7. Loh Y., Oyama Y., Statkute L., et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 2007, 109:2643-2648.
8. Daikeler T., Labopin M., Di Gioia M., et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood 2011, 118:1693-1698.
9. Sanz J., Arango M., Carpio N., et al. Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience. Bone Marrow Transplant 2014, 49:1084-1088.
10. O'Brien T.A., Eastlund T., Peters C., et al. Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases. Br J Haematol 2004, 127:67-75.
11. Page K.M., Mendizabal A.M., Prasad V.K., et al. Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. Biol Blood Marrow Transplant 2008, 14:1108-1117.
12. Horn B., Viele M., Mentzer W., et al. Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation. Bone Marrow Transplant 1999, 24:1009-1013.
13. Cwynarski K., Goulding R., Pocock C., et al. Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions. Bone Marrow Transplant 2001, 28:581-586.
14. Daikeler T., Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2007, 20:349-360.
15. Jacobson C.A., Sun L., Kim H.T., et al. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014, 20:668-675.
16. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009, 113:3865-3874.
17. Lesley R., Xu Y., Kalled S.L., et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
18. Thien M., Phan T.G., Gardam S., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
19. Issitt P.D., Combs M.R., Bumgarner D.J., et al. Studies of antibodies in the sera of patients who have made red cell autoantibodies. Transfusion 1996, 36:481-486.
20. Young P.P., Uzieblo A., Trulock E., et al. Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia?. Transfusion 2004, 44:67-72.
21. Ahrens N., Pruss A., Kähne A., et al. Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion. Transfusion 2007, 47:813-816.
22. Sigler E., Shvidel L., Yahalom V., et al. Clinical significance of serologic markers related to red blood cell autoantibodies production after red blood cell transfusion-severe autoimmune hemolytic anemia occurring after transfusion and alloimmunization: successful treatment with rituximab. Transfusion 2009, 49:1370-1374.
23. Guirat-Dhouib N., Mezri M., Hmida H., et al. High frequency of autoimmunization among transfusion-dependent Tunisian thalassaemia patients. Transfus Apher Sci 2011, 45:199-202.
24. Mqadmi A., Zheng X., Yazdanbakhsh K. CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. Blood 2005, 105:3746-3748.
25. Yu J., Heck S., Yazdanbakhsh K. Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models. Am J Hematol 2007, 82:691-696.
26. Bashey A., Owen I., Lucas G.F., et al. Late onset immune pancytopenia following bone marrow transplantation. Br J Haematol 1991, 78:268-274.
27. Ship A., May W., Lucas K. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation. Bone Marrow Transplant 2002, 29:365-366.
28. Corti P., Bonanomi S., Vallinoto C., et al. Rituximab for immune hemolytic anemia following T- and B-Cell-depleted hematopoietic stem cell transplantation. Acta Haematol 2003, 109:43-45.
29. Raj K., Narayanan S., Augustson B., et al. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. Bone Marrow Transplant 2005, 35:299-301.
30. Barros M.M.O., Blajchman M.A., Bordin J.O. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfus Med Rev 2010, 24:195-210.
31. Birgens H., Frederiksen H., Hasselbalch H.C., et al. Aphase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol 2013, 163:393-399.